Table 2 Clinicopathologic characteristics of patients by PD-L1 expression

age

0.01

0.06

≤ 50

12(30.0%)

28(70%)

9(22.5%)

31(77.5%)

>50

11(11.0%)

89(89%)

10(10.0%)

90(90.0%)

tumor size

0.221

0.101

≤ 2.0 cm

11 (13.3%)

72 (86.7%)

8(9.6%)

75 (90.4%)

> 2.0 cm

12 (21.1%)

45 (78.9%)

11 (19.3%)

46 (80.7%)

Menopausal status

0.011

0.001

postmenopausal

10 (10.8%)

83 (89.2%)

9 (9.7%)

84(90.3%)

menstruating

13 (27.7%)

34 (72.3%)

10(21.3%)

37(78.7%)

Histological subtype

0.138

0.459

IDC

21(18.8%)

91(81.2%)

14(13.0%)

98(87.0%)

ILC

2(7.1%)

26(92.9%)

5(17.9%)

23(82.1%)

Histological classification of IDC

0.117

0.001

I

3 (10.3%)

26 (89.7%)

0(0.0%)

29(100.0%)

II

6 (17.1%)

29 (82.9%)

4(11.4%)

31(88.6%)

III

12 (25.0%)

36(75.0%)

10(20.8%)

38(79.2%)

Nodal metastasis

< 0.01

0.066

Present

19(30.6%)

43(69.4%)

12(19.4%)

50(80.6%)

Absent

4(5.1%)

74(94.9%)

7(9.0%)

71(91.0%)

Lymphovascular Invasion

< 0.01

< 0.01

Present

18(41.9%)

25(58.1%)

14 (32.6%)

29 (67.4%)

Absent

5(5.1%)

92(94.9%)

5 (5.1%)

92 (94.9%)

Ki-67 Index

0.064

0.076

<14%

9(27.2%)

24(72.3%)

8(24.2%)

25(75.8)

>14%

14(13.1%)

93 (86.9%)

11(10.3%)

96(89.7%)

TNM Clinical Stage

< 0.01

< 0.01

I ~ II

7 (7.1%)

91 (92.9%)

6(6.1%)

92(93.9%)

III ~ IV

16 (38.1%)

26 (61.9%)

13(31.0%)

29(69.0%)

ER

0.001

< 0.01

Positive

6(7.3%)

76(92.7%)

2(2.4%)

80(97.6)

Negative

17(29.3%)

41(70.7%)

17(29.3%)

41(70.7%)

PR

0.104

0.007

Positive

2(6.1%)

31(93.9%)

0(0%)

33(100%)

Negative

21(19.6%)

86(80.4%)

19(17.8%)

88(82.2%)

HER-2

0.596

0.004

Positive

6(16.2%)

31(83.8%)

5(13.5%)

32(86.5%)

Negative

17(16.5%)

86(83.5%)

14(13.6%)

89(86.4%)